Altered splicing leads to reduced activation of CPEB3 in high-grade gliomas

Magdalena Skubal1, Gerrit H Gielen2, Anke Waha2

  • 1Institute of Cellular Neurosciences, Medical Faculty, University of Bonn, 53105 Bonn, Germany.

Oncotarget
|June 4, 2016
PubMed

Insights

Cytoplasmic polyadenylation element binding proteins (CPEBs) are implicated in glioma. Hypermethylation of CPEB1 and altered CPEB3 splicing contribute to tumor progression and malignancy.

Area of Science:

  • Neuro-oncology
  • Molecular biology
  • Epigenetics

Background:

  • Cytoplasmic polyadenylation element binding proteins (CPEBs) regulate mRNA translation and are involved in cell cycle control and senescence.
  • Gliomas are the most common primary brain tumors in humans, necessitating research into their molecular pathology.

Purpose of the Study:

  • To investigate the role of CPEB1-4 in the molecular pathology of gliomas.
  • To identify potential epigenetic and post-transcriptional regulatory mechanisms affecting CPEB function in gliomas.

Main Methods:

  • Methylation analysis of CPEB1-4 promoter regions in glioma samples.
  • Quantitative analysis of CPEB protein expression and correlation with tumor grade.
  • Investigation of alternative splicing variants of CPEB3 in relation to tumor progression.

Main Results:

  • CPEB1 gene hypermethylation was identified in glioma samples, correlating with decreased protein expression and higher tumor grade.
  • CPEB3 expression positively correlated with glioma progression and malignancy.
  • Alternative splicing of CPEB3, leading to loss of the B-region, was associated with reduced protein activity in high-grade gliomas.

Conclusions:

  • Deregulation of CPEB proteins, via epigenetic mechanisms (e.g., hypermethylation) and alternative mRNA splicing, is a frequent event in gliomas.
  • Altered CPEB function may contribute to glioma development and progression.
  • Aberrant splicing generates CPEB isoforms with impaired biological functions, impacting glioma pathology.